Resonance Health upgrades FY26 profit guidance
Perth-based medical technology firm Resonance Health (ASX:RHT) announced an upgrade to its financial guidance for the year ending June 30, driven by robust operational performance and an aggressive expansion into high-margin sectors.
The company now forecasts an underlying EBITDA of approximately $2.6 million, representing a substantial 30% increase over previous estimates of $2 million.
The profitability boost comes despite a slight downward revision in annual revenue projections to $16 million, a shift attributed primarily to the timing of revenue recognition for a major $13.8 million clinical trial agreement, with a larger portion of that contract now expected to materialise in FY27.
The upgrade highlights Resonance’s evolving business model, which increasingly prioritises Software-as-a-Medical-Device and clinical trial services.
The higher-margin activities have propelled the company's expected underlying EBITDA margin to 16.3%, well ahead of earlier forecasts.
Management maintains that this margin expansion is underpinned by disciplined cost control and improved operating leverage rather than one-off items.
The result serves as a critical milestone in the company’s medium-term strategy to scale annual revenue towards $30 million while targeting an underlying EBITDA margin of 25%.
At the time of reporting, Resonance Health's share price was $0.050.
Frequently asked questions
More from Australia
Resurgent inflation pressures test key Australian consumer shares
The digital cart rush redefining Australian retail profit pools
Trans-Tasman insurers battle contract churn while defending profit margins
Capital battles heat up as takeover offers challenge listed housing operators
The equities fueling the next infrastructure supercycle
Crypto networks collide with sanctions in a fight for financial access
